keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis b treatment guidelines

keyword
https://www.readbyqxmd.com/read/28073407/-the-practice-guideline-on-prophylaxis-and-treatment-of-hepatitis-b-for-liver-transplantation-in-china-2016-edition
#1
(no author information available yet)
No abstract text is available yet for this article.
December 20, 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/28052620/when-can-we-stop-nucleoside-analogues-in-patients-with-chronic-hepatitis-b
#2
REVIEW
Chern Hao Chong, Seng Gee Lim
Treatment with nucleoside analogue (NAs) is now the most common treatment for chronic hepatitis B (CHB) and is recommended by all guidelines. Stopping NAs is a controversial issue in these patients, unless the clinical endpoints of HBeAg seroconversion or HBsAg seroclearance are achieved. While HBeAg seroconversion can occur in a significant number of patients, HBsAg seroclearance rates are low. HBsAg seroclearance is increasingly accepted as the ideal end of treatment, representing a functional cure. Treatment withdrawal leads to relapse in 50% of patients who achieve HBeAg seroconversion and complete at least 12 months of consolidation therapy...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28028371/genotype-specific-peripheral-lipid-profile-changes-with-hepatitis-c-therapy
#3
Mark R Pedersen, Amit Patel, David Backstedt, Myunghan Choi, Anil B Seetharam
AIM: To evaluate magnitude/direction of changes in peripheral lipid profiles in patients undergoing direct acting therapy for hepatitis C by genotype. METHODS: Mono-infected patients with hepatitis C were treated with guideline-based DAAs at a university-based liver clinic. Patient characteristics and laboratory values were collected before and after the treatment period. Baseline demographics included age, ethnicity, hypertension, diabetes, hyperlipidemia, treatment regimen, and fibrosis stage...
December 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27976461/safety-and-efficacy-of-direct-acting-antivirals-for-the-treatment-of-chronic-hepatitis-c-in-a-real-world-population-aged-65-years-and-older
#4
Fabio Conti, Stefano Brillanti, Federica Buonfiglioli, Ranka Vukotic, Maria Cristina Morelli, Claudine Lalanne, Marco Massari, Francesco Giuseppe Foschi, Veronica Bernabucci, Ilaria Serio, Gian Maria Prati, Elisa Negri, Lorenzo Badia, Paolo Caraceni, Paolo Muratori, Giovanni Vitale, Alberto Porro, Marta Morotti, Giuseppe Mazzella, Pietro Andreone
The availability of direct acting antiviral agents (DAA) regimens has expanded the pool of patients eligible for treatment. However, data on the virological response and tolerability of DAAs in elderly patients are lacking. We evaluated the efficacy and safety of DAAs in patients with advanced fibrosis/cirrhosis in real-life practice with the focus on those aged ≥65 years. Between January and December 2015, all consecutive patients with HCV-related advanced fibrosis/cirrhosis treated with DAA at eleven tertiary referral centers in Emilia Romagna (Italy) were enrolled...
December 15, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27933202/screening-and-management-of-viral-hepatitis-and-hepatocellular-carcinoma-in-mongolia-results-from-a-survey-of-mongolian-physicians-from-all-major-provinces-of-mongolia
#5
Yoona A Kim, Jacqueline Estevez, An Le, Dennis Israelski, Oidov Baatarkhuu, Tserenchimed Sarantuya, Sonom Narantsetseg, Pagbajabyn Nymadawa, Richard H Le, Man-Fung Yuen, Geoffrey Dusheiko, Mario Rizzetto, Mindie H Nguyen
BACKGROUND: According to Globocan, Mongolia has the highest worldwide hepatocellular carcinoma (HCC) incidence (78.1/100 000, 3.5× higher than China). AIMS AND METHODS: We conducted an anonymous survey of physicians from major provinces who attended an educational liver symposium, analysing their demography, practice, knowledge, perceptions and proposed solutions. Multivariate logistic regression was used to estimate OR relating demography and practice factors with higher provider knowledge and improvement...
2016: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/27891360/why-should-viral-markers-be-mandatory-in-ocular-surgeries-a-hospital-based-retrospective-study
#6
Anita Ambastha, Rakhi Kusumesh, Gyan Bhasker
INTRODUCTION: Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus I, II (HIV-I,II) are serious global and public health problem. Knowledge of the seroprevalence would enable early diagnosis, treatment of patients and also help in prevention of horizontal spread of infection by application of universal infection control measures. AIM: To determine the seroprevalence of HBV, HCV and HIV I, II infection in patients undergoing ocular surgery...
October 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27888600/-darunavir-cobicistat-monotherapy-experience-in-a-tertiary-hospital
#7
L Yunquera-Romero, R Asensi-Díez, J C Del Rio-Valencia, I Muñoz-Castillo, M A Castaño-Carracedo
OBJECTIVE: Ritonavir-boosted protease inhibitor (IP/r) monotherapy: darunavir/ritonavir (DRV/r) or lopinavir/ritonavir (LPV/r) monotherapy is only provided in the major treatment guidelines in pretreated patients to prevent toxicity associated with nucleoside/nucleotide reverse transcriptase inhibitor (NRTI), reduce costs and simplify antiretroviral treatment. To start IP/r monotherapy, according to GESIDA guidelines 2016, patients need to meet the following criteria: absence of chronic hepatitis B, plasma viral load <50 copies/ mL for at least 6 months and absence of protease inhibitors mutations or previous virologic failures to IP/r...
December 2016: Revista Española de Quimioterapia: Publicación Oficial de la Sociedad Española de Quimioterapia
https://www.readbyqxmd.com/read/27867437/sero-prevalence-and-correlates-of-hepatitis-b-and-c-co-infection-among-hiv-infected-individuals-in-two-regional-hospitals-in-cameroon
#8
Henry Namme Luma, Servais Albert Fiacre Bagnaka Eloumou, Domin Sone Majunda Ekaney, Fernando Kemta Lekpa, Olivier Donfack-Sontsa, Bertrand Hugo Mbatchou Ngahane, Yacouba Njankouo Mapoure
BACKGROUND: Liver disease related to Hepatitis B (HBV) and C (HCV) infection has become a major cause of morbidity and mortality in HIV/AIDS patients. Data on the prevalence of HBV and HCV in Cameroon remains inconclusive. OBJECTIVE: We aimed to determine the sero-prevalence and correlates of Hepatitis markers in HIV/AIDS patients in two Regional Hospitals. METHODS: A cross-sectional study carried out from December 2014 to March 2015. HIV/AIDS patients aged 21 were included and above, receiving care at HIV treatment centres...
2016: Open AIDS Journal
https://www.readbyqxmd.com/read/27811627/provider-patient-and-practice-factors-shape-hepatitis-b-prevention-and-management-by-primary-care-providers
#9
Nizar A Mukhtar, Priya Kathpalia, Joan F Hilton, Gene Lau, Albert Yu, Kevin Grumbach, Tung T Nguyen, Daniel Chan, Mandana Khalili
GOALS: To evaluate provider knowledge, attitudes and barriers to hepatitis B virus (HBV) care and management practices across diverse primary care settings. BACKGROUND: Factors influencing adherence to recommended HBV screening and management guidelines are poorly defined. MATERIALS AND METHODS: Providers across various health care settings in San Francisco were surveyed. Multivariate analyses were used to identify factors associated with recommended HBV screening, vaccination, and disease monitoring...
November 2, 2016: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/27800206/immune-complex-mediated-glomerulonephritis-with-acute-thrombotic-microangiopathy-following-newly-detected-hepatitis-b-virus-infection-in-a-kidney-transplant-recipient
#10
Tracey Salter, Hannah Burton, Sam Douthwaite, William Newsholme, Catherine Horsfield, Rachel Hilton
Hepatitis B virus (HBV) presents a risk to patients and staff in renal units. To minimise viral transmission, there are international and UK guidelines recommending HBV immunisation for patients commencing renal replacement therapy (RRT) and HBV surveillance in kidney transplant recipients. We report the case of a 56-year-old male who was immunised against HBV before starting haemodialysis. He received a deceased donor kidney transplant three years later, at which time there was no evidence of HBV infection...
2016: Case Reports in Transplantation
https://www.readbyqxmd.com/read/27784957/antiviral-therapy-of-hepatitis-c-as-curative-treatment-of-indolent-b-cell-lymphoma
#11
REVIEW
Michele Merli, Giuseppe Carli, Luca Arcaini, Carlo Visco
The association of hepatitis C virus (HCV) and B-cell non-Hodgkin lymphomas (NHL) has been highlighted by several epidemiological and biological insights; however the most convincing evidence is represented by interventional studies demonstrating the capability of antiviral treatment (AT) with interferon (IFN) with or without ribavirin to induce the regression of indolent lymphomas, especially of marginal-zone origin. In the largest published retrospective study (100 patients) the overall response rate (ORR) after first-line IFN-based AT was 77% (44% complete responses) and responses were sustainable (median duration of response 33 mo)...
October 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27777892/hepatitis-b-management-in-the-pregnant-patient-an-update
#12
Walid S Ayoub, Erica Cohen
Chronic hepatitis B is a worldwide disease, with significant burden on health care systems. While universal vaccination programs have led to an overall decrease in incidence of transmission of hepatitis B, unfortunately, there remain large areas in the world where vaccination against hepatitis B is not practiced. In addition, vertical transmission of hepatitis B persists as a major concern. Hepatitis B treatment of the pregnant patient requires a thorough assessment of disease activity and close monitoring for flares, regardless of initiation of antiviral therapy...
September 28, 2016: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/27761440/treatment-strategies-according-to-genotype-for-chronic-hepatitis-b-in-children
#13
REVIEW
Seung Man Cho, Byung-Ho Choe
This review article was requested by editor-in-chief of this journal as 'pediatric CHB treatment' for the upcoming special issue. The main objective of chronic hepatitis B (CHB) treatment is diminishing the risk of complications related to chronic liver disease. In Asia, there are already some reports about hepatocellular carcinoma (HCC) in hepatitis B virus (HBV) infected children. The key points of treatment in children with CHB infections are selection of which patients to treat and conformation of the optimal therapy time that would reduce viral resistance...
September 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27761439/immune-therapy-for-hepatitis-b
#14
REVIEW
Sheikh Mohammad Fazle Akbar, Mamun Al-Mahtab, Md Sakilur Islam Khan, Ruksana Raihan, Ananta Shrestha
Although several antiviral drugs are now available for treatment of patients with chronic hepatitis B (CHB), sustained off-treatment clinical responses and containment of CHB-related complications are not achieved in majority of CHB patients by antiviral therapy. In addition, use of these drugs is endowed with substantial long term risk of viral resistance and drug toxicity. The infinite treatment regimens of antiviral drugs for CHB patients are also costly and usually unbearable by most patients of developing and resource-constrained countries...
September 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27755152/hepatocellular-carcinoma-in-patients-with-hiv
#15
Imane El Dika, James J Harding, Ghassan K Abou-Alfa
PURPOSE OF REVIEW: Hepatocellular carcinoma (HCC) is becoming an important cause of mortality in patients with HIV, attributed to coinfection with hepatitis C virus, hepatitis B virus, and the longer survival advantage these patients are achieving after introducing the highly active antiretroviral therapy (HAART) regimens. RECENT FINDINGS: In addition to hepatitis infection, immunosuppression secondary to HIV infection, direct impact of the virus on liver parenchyma, and the use of hepatotoxic antiretroviral drugs, all contribute to HCC pathogenesis...
January 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/27746888/primary-hepatic-lymphoma-a-retrospective-multicenter-rare-cancer-network-study
#16
Gamze Ugurluer, Robert C Miller, Yexiong Li, Juliette Thariat, Pirus Ghadjar, Ulrike Schick, Mahmut Ozsahin
Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through the Rare Cancer Network (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23-86 years) with a male-to-female ratio of 1.9:1.0. Abdominal pain or discomfort was the most common presenting symptom. Regarding B-symptoms, 19.5% of patients had fever, 17.1% weight loss, and 9.8% night sweats. The most common radiological presentation was multiple lesions...
September 5, 2016: Rare Tumors
https://www.readbyqxmd.com/read/27734775/-tracing-patients-with-chronic-viral-hepatitis
#17
A G Spruijt, K R Wilting, G D Mithoe, W J M Niessen
OBJECTIVE: To investigate the effect of an intervention in which medical-microbiological laboratories alert general practitioners (GPs) in writing about patients with a chronic hepatitis B or C infection in their practice, urging them to bring these patients under medical surveillance again now that treatment options have improved and guidelines have been revised. DESIGN: Descriptive, prospective. METHOD: All patients who had been diagnosed with hepatitis B or C between 2003 and 2013 on the request of the GP, and for whom diagnostics by an internist, infectious diseases specialist or gastrointestinal/liver specialist had never been requested, were included...
2016: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/27711945/-laboratory-requirements-to-diagnose-viral-hepatitis-under-the%C3%A2-development-of-guidelines
#18
Hans Becker, Jona Theodor Stahmeyer, Michael P Manns, Christian Krauth, Markus Cornberg
Infections with hepatitis B-, C- and D- viruses have a significant health burden. In Germany, the seroprevalence of HBs-Ag is calculated with 0.6 % and of HCV-antibodies with 0.3 %. However, most patients are not diagnosed. Sequelae are liver-cirrhosis and hepatocellular carcinoma. Several S3-guidelines for the diagnosis and treatment of viral hepatitis have been established. However, implementation of guidelines is not easy to evaluate. To estimate the changes of medical knowledge and diagnostic procedures about viral hepatitis, 7 parameters of liver-diagnostics were elected to analyze the requirements profile in the years 2005 - 2011 in 4 German federal states...
January 2017: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/27708965/viral-hepatitis-screening-guideline-before-biological-drug-use-in-rheumatic-patients
#19
Ömer Karadağ, Timuçin Kaşifoğlu, Birol Özer, Sabahattin Kaymakoğlu, Yeşim Kuş, Murat İnanç, Gökhan Keser, Sedat Kiraz
Biological drugs (tumor necrosis factor inhibitors, rituximab, tocilizumab, abatacept, and tofacitinib) are important treatment alternatives in rheumatology, particularly for resistant patients. However, they may cause hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation; for instance, HBV reactivation may occur in a patient who is an inactive hepatitis B surface antigen (HBsAg) carrier or who has resolved HBV infection. Therefore, the screening of patients before biological treatment and the application of a prophylactic treatment, particularly with respect to latent HBV infections, are recommended when necessary...
March 2016: European Journal of Rheumatology
https://www.readbyqxmd.com/read/27680170/advanced-liver-injury-in-patients-with-chronic-hepatitis-b-and-viral-load-below-2-000-iu-ml
#20
Valter Oberdan Borges de Oliveira, Juliana Passos Rocha Oliveira, Eloy Vianey Carvalho de França, Hugo Leite de Farias Brito, Tereza Virgínia Nascimento, Alex França
Introduction: According to the guidelines, the viral load of 2,000 IU/mL is considered the level to differentiate between inactive carriers and HBeAg(-) chronic hepatitis B patients. Even so, liver damage may be present in patients with lower viral load levels, mainly related to regional variations. This study aims to verify the presence of liver injury in patients with viral load below 2,000 IU/mL. Methods: Patients presenting HBsAg(+) for more than six months, Anti-HBe(+)/HBeAg(-), viral load below 2,000 IU/mL and serum ALT levels less than twice the upper limit of normality underwent liver biopsy...
September 22, 2016: Revista do Instituto de Medicina Tropical de São Paulo
keyword
keyword
53701
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"